Remyelination varies between and within lesions in multiple sclerosis following bexarotene

In multiple sclerosis chronic demyelination is associated with axonal loss, and ultimately contributes to irreversible progressive disability. Enhancing remyelination may slow, or even reverse, disability. We recently trialled bexarotene versus placebo in 49 people with multiple sclerosis. While the primary MRI outcome was negative, there was converging neurophysiological and MRI evidence of efficacy. Multiple factors influence lesion remyelination. In this study we undertook a systematic exploratory analysis to determine whether treatment response – measured by change in magnetisation transfer ratio – is influenced by location (tissue type and proximity to CSF) or the degree of abnormality (using baseline magnetisation transfer ratio and T1 values).

[1]  D. MacManus,et al.  Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study , 2021, The Lancet Neurology.

[2]  D. Reich,et al.  7T MRI Differentiates Remyelinated from Demyelinated Multiple Sclerosis Lesions , 2021, Annals of neurology.

[3]  R. Reynolds,et al.  Surface-in pathology in multiple sclerosis: a new view on pathogenesis? , 2021, Brain : a journal of neurology.

[4]  Yi Wang,et al.  Pathologic correlates of the magnetization transfer ratio in multiple sclerosis , 2020, Neurology.

[5]  R. Franklin,et al.  The Role of Astrocytes in Remyelination , 2020, Trends in Neurosciences.

[6]  R. Franklin,et al.  Remyelination and ageing: Reversing the ravages of time , 2019, Multiple sclerosis.

[7]  A. Coles,et al.  Promoting remyelination in multiple sclerosis , 2019, Journal of Neurology.

[8]  S. Hauser,et al.  Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial , 2017, The Lancet.

[9]  R. Franklin,et al.  Regenerating CNS myelin — from mechanisms to experimental medicines , 2017, Nature Reviews Neuroscience.

[10]  J. Geurts,et al.  Cortical Remyelination Is Heterogeneous in Multiple Sclerosis , 2017, Journal of neuropathology and experimental neurology.

[11]  S. Galetta,et al.  Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial , 2017, The Lancet Neurology.

[12]  David H. Miller,et al.  An abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis , 2017, Brain : a journal of neurology.

[13]  D. Arnold,et al.  Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study , 2016, Journal of Neurology.

[14]  Mattia Veronese,et al.  Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis , 2016, Annals of neurology.

[15]  Peter R Luijten,et al.  Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study. , 2016, Brain : a journal of neurology.

[16]  David H. Miller,et al.  Magnetization transfer ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple sclerosis. , 2015, Brain : a journal of neurology.

[17]  D. Miller,et al.  Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis. , 2014, Multiple sclerosis and related disorders.

[18]  L. Kappos,et al.  Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing–remitting multiple sclerosis , 2014, Multiple sclerosis.

[19]  Douglas L. Arnold,et al.  Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis , 2013, NeuroImage.

[20]  Elizabeth Fisher,et al.  Clinically feasible MTR is sensitive to cortical demyelination in MS , 2013, Neurology.

[21]  B. Trapp,et al.  Cortical remyelination: A new target for repair therapies in multiple sclerosis , 2012, Annals of neurology.

[22]  R. Franklin,et al.  Neuroprotection and repair in multiple sclerosis , 2012, Nature Reviews Neurology.

[23]  H. Lassmann,et al.  Review: The architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis , 2011, Neuropathology and applied neurobiology.

[24]  R. Reynolds,et al.  A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis , 2010, Annals of neurology.

[25]  Klaus-Armin Nave,et al.  Myelination and the trophic support of long axons , 2010, Nature Reviews Neuroscience.

[26]  David H. Miller,et al.  High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. , 2010, Brain : a journal of neurology.

[27]  Hans Lassmann,et al.  The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.

[28]  Christine Stadelmann,et al.  Extensive Cortical Remyelination in Patients with Chronic Multiple Sclerosis , 2007, Brain pathology.

[29]  C. Laule,et al.  Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology , 2006, Multiple sclerosis.

[30]  David H. Miller,et al.  Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain , 2004, Annals of neurology.

[31]  Stephen J. Jones,et al.  Serial magnetization transfer imaging in acute optic neuritis. , 2003, Brain : a journal of neurology.

[32]  Frederik Barkhof,et al.  Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. , 2003, Archives of neurology.

[33]  B. Trapp,et al.  Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients , 2003, Journal of neuropathology and experimental neurology.

[34]  E. Cho,et al.  Immunopathology of secondary‐progressive multiple sclerosis , 2001, Annals of neurology.

[35]  C. Lucchinetti,et al.  A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions , 2001, Annals of neurology.

[36]  R. Henkelman,et al.  Magnetization transfer in MRI: a review , 2001, NMR in biomedicine.

[37]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[38]  T Revesz,et al.  Multiple sclerosis. Pathology of recurrent lesions. , 1993, Brain : a journal of neurology.

[39]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.